Unicycive Q3 Loss Widens to $21.5M; $59M Cash Funds Runway Past PDUFA
UNCY is trading near its 52-week low of $3.33 (6.6% above the low).
Summary
Unicycive's Q3 2026 10-Q shows a $21.5M nine-month net loss and $59.0M of cash and securities — enough runway to clear the March 25, 2027 OLC PDUFA date — while a second securities class action has been consolidated with the first.
Key Events · Earnings and Guidance · UNCY
-
Nine-Month Net Loss Widens to $21.5M
Net loss was $21.5M for the nine months ended September 30, 2026, versus $11.9M a year earlier, on total operating expenses of $27.4M.
-
G&A Jump Driven by Launch Prep
General and administrative expense rose 35% to $20.8M, including $1.5M of commercial launch preparation and $2.2M more non-cash stock compensation than the prior year.
-
$59M Liquidity After $39.3M ATM Raise
Cash and cash equivalents of $42.0M plus $17.0M of corporate bonds total $59.0M; the company sold 6,293,966 shares at an average $6.44 for $39.3M net proceeds in the first nine months.
-
Runway Extends Past March 2027 PDUFA
Management states current cash funds operations for more than 12 months from the filing date, covering the March 25, 2027 FDA action date for oxylanthanum carbonate.
Analysis · UNCY · Life Sciences
The nine-month net loss nearly doubled to $21.5M from $11.9M, driven mostly by a 35% jump in G&A to $20.8M that includes $1.5M of commercial launch preparation and $5.4M of non-cash stock compensation. Against that burn, the balance sheet still holds $59.0M in cash and marketable securities after raising $39.3M net through the ATM in the first nine months, and management states resources cover more than 12 months — which carries the company past the March 25, 2027 PDUFA date for oxylanthanum carbonate. The reported loss overstates cash burn: operating cash use was $21.1M, and the $4.5M warrant fair-value gain is a non-cash mark-to-market, not a cash inflow. The main overhang remains legal — a second securities class action filed September 3, 2026 has been related to the earlier Elkhodari case, with derivative suits stayed pending the motion to dismiss.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, UNCY was trading at $3.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $98.9M. The 52-week trading range was $3.33 to $8.74. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.